CENP-O, a protein localized at the centromere throughout the cell cycle, is a novel target antigen in systemic sclerosis

Journal of Rheumatology

Volumn 36, Issue 4, 2009, Pages 781-786

  Saito, Akiko ^a   Muro, Yoshinao ^a   Sugiura, Kazumitsu ^a   Ikeno, Masashi ^b   Yoda, Kinya ^c   Tomita, Yasushi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

Autoantibody; Centromere; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; CENTROMERE PROTEIN O; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; ANTIGEN; AUTOANTIBODY; CENP O PROTEIN, HUMAN; CENP-O PROTEIN, HUMAN; DNA BINDING PROTEIN; NONHISTONE PROTEIN;

ADULT; ANTIGEN STRUCTURE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL CYCLE; CENTROMERE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCLERODERMA; SERUM; SYSTEMIC SCLEROSIS; WESTERN BLOTTING; AGED; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; ANTIGENS; AUTOANTIBODIES; CELL CYCLE; CENTROMERE; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; FEMALE; HELA CELLS; HUMANS; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 66149105126     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080726     Document Type: Article

References (26)

1. Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM. Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 1993;32:297-301.
2. Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S, Gejyo F. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol 2000;27:1403-7.
3. Katano K, Kawano M, Koni I, Sugai S, Muro Y. Clinical and laboratory features of anticentromere antibody positive primary Sjögren's syndrome. J Rheumatol 2001;28:2238-44.
4. Earnshaw W, Bordwell B, Marino C, Rothfield N. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest 1986;77:426-30.
5. Muro Y, Sugimoto K, Okazaki T, Ohashi M. The heterogeneity of anticentromere antibodies in immunoblotting analysis. J Rheumatol 1990;17:1042-7.
6. Obuse C, Yang H, Nozaki N, Goto S, Okazaki T, Yoda K. Proteomics analysis of the centromere complex from HeLa interphase cells: UV-damaged DNA binding protein 1 (DDB-1) is a component of the CEN-complex, while BMI-1 is transiently co-localized with the centromeric region in interphase. Genes Cells 2004;9:105-20.
7. Izuta H, Ikeno M, Suzuki N, et al. Comprehensive analysis of the ICEN (interphase centromere complex) components enriched in the CENP-A chromatin of human cells. Genes Cells 2006;11:673-84.
8. Foltz DR, Jansen LE, Black BE, Bailey AO, Yates JR 3rd, Cleveland DW. The human CENP-A centromeric nucleosome-associated complex. Nat Cell Biol 2006;8:458-69.
9. Okada M, Cheeseman IM, Hori T, et al. The CENP-H-I complex is required for the efficient incorporation of newly synthesized CENP-A into centromeres. Nat Cell Biol 2006;8:446-57.
10. Hori T, Okada M, Maenaka K, Fukagawa T. CENP-O-class proteins form a stable complex and are required for proper kinetochore function. Mol Biol Cell 2008;19:843-54.
11. Watanabe A, Kodera M, Sugiura K, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892-900.
12. Takehara K, Sato S. The classification of pathogenesis and the development of therapy in systemic sclerosis: the classification of severity and the guideline for treatment (2004). A research project for systemic sclerosis supported by the Ministry of Health, Labour and Welfare of Japan [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2004.
13. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
14. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
15. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity. Mod Rheumatol 2004;14:425-34.
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
17. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
18. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
19. Muro Y, Kano T, Sugiura K, Hagiwara M. Low frequency of autoantibodies against Ki-67 antigen in Japanese patients with systemic autoimmune diseases. J Autoimmun 1997;10:499-503.
20. Iwai T, Muro Y, Sugimoto K, Matsumoto Y, Ohashi M. Clinical features of anti-chromo antibodies associated with anti-centromere antibodies. Clin Exp Immunol 1996;105:285-90.
21. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
22. Tan EM, Muro Y, Pollard KM. Autoantibody-defined epitopes on nuclear antigens are conserved, conformation-dependent and active site regions. Clin Exp Rheumatol 1994;12 Suppl 11:27-31.
23. Ogawa Y, Sugiura K, Watanabe A, et al. Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J Autoimmun 2004;23:221-31.
24. Kass S, Tyc K, Steitz JA, Sollner-Webb B. The U3 small nucleolar ribonucleoprotein functions in the first step of preribosomal RNA processing. Cell 1990;60:897-908.
25. Ochs RL, Lischwe MA, Spohn WH, Busch H. Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biol Cell 1985;54:123-33.
26. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999;190:815-26.